Physicians' Academy for Cardiovascular Education

Update on ACCF/AHA Heart Failure guidelines

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Literature - Yancy CW, Jessup M, Bozkurt B, et al. - Circulation 2017, Epub ahead of print

This document concerns an update of the “2013 ACCF/AHA Guidelines for the Management of Heart Failure” [1] in areas in which new evidence has emerged since this publication. To achieve this, and for future publishes, the Heart Failure Society of America (HFSA) has partnered.

This update represents the second part of a 2-stage publication; the first part has been published as the “2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure” [2]. This first part included guidance on new therapies, including an angiotensin receptor-neprilysin inhibitor (ARNI) and a sinoatrial node modulator.

The current second part of the document includes revision of the 2013 sections on biomarkers, new therapies indicated for stage C heart failure (HF) with reduced ejection fraction (HFrEF), updates on HF with preserved ejection fraction (HFpEF), new data on important comorbidities and new insights into the prevention of HF.


Show references

Find this article online at Circulation

Share this page with your colleagues and friends: